Autolomous and Cellular Origins Expand Cell Therapy Manufacturing Process
Officials at Autolomous and Cellular Origins say the companies have carried out the end-to-end integration of their respective platforms to bring full automation and digitization to the entire cell therapy manufacturing process. This new scalable approach creates a connected manufacturing environment that gives developers greater standardization, traceability, and control across the entire manufacturing process, according to the companies’ spokespersons.
Cellular Origins’ Constellation® automated platform was created to enable cell therapy manufacturing, integrating mobile robotics, existing bioprocessing technologies, and sterile fluid transfer into a coordinated operation. Its flexible, modular architecture allows developers and manufacturers to scale manufacturing capacity as demand grows while maintaining standardized processes, avoiding therapy redevelopment and reducing scale-up risk, notes Edwin Stone, CEO of Cellular Origins.
Autolomous’ digital autoloMATE® platform was designed to allow real-time data exchange and integration across existing software and AI systems, as well as devices and robotic platforms across the entire manufacturing process and supply chain, while safeguarding intellectual property. The modular architecture allows each deployment to be configured to customer needs.
The combined solution overcomes fragmentation, limited visibility, and the absence of standardized, interoperable data flows without replacing existing processes, enabling manufacturers to scale to commercially viable levels, maintains Alexander Seyf, CEO of Autolomous. First integrations have already been achieved at the Cell and Gene Therapy Catapult Digital and Automation Testbeds, as part of an Innovate UK-funded project.
“Scientific ambition has never been the bottleneck in bringing innovative cell therapy to patients, but the delivery infrastructure has brought many challenges,” continues Seyf. “Together with Cellular Origins, we enable fast and efficient scaling from research through to patient administration, ensuring standardization, automation and digitization across the entire process.”
“Scaling cell therapy manufacturing is not just a question of employing automation. It requires a manufacturing system that can evolve with demand,” adds Stone. “Our collaboration with Autolomous, and joint work with the Cell and Gene Therapy Catapult, clearly demonstrates how robotic platforms and digital infrastructure can operate as one.”
The post Autolomous and Cellular Origins Expand Cell Therapy Manufacturing Process appeared first on GEN – Genetic Engineering and Biotechnology News.
STAT+: Amylyx nears pivotal endocrine drug study readout
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Later this quarter, Amylyx Pharmaceuticals will read out results from a study evaluating a new treatment for a rare endocrine disorder. It’s a pivotal moment that could support the drug’s approval and comes two years after Amylyx was rocked — and lauded — for voluntarily pulling a drug for ALS off the market because a follow-on study showed it wasn’t helping patients.
The Amylyx drug, avexitide, is being developed to halt severe, uncontrolled drops in blood sugar that some people experience after undergoing stomach-reducing surgery for weight loss.
Nitinol supplier Fort Wayne Metals sold
Axel Johnson Inc. (AJI) has acquired Fort Wayne Metals and the medtech nitinol supplier’s parent company, Fort Wayne Metals Research Products. Terms of the sale were not disclosed. Founded in 1970 by Ardelle Glaze and most recently led and owned by his son Scott Glaze, Fort Wayne Metals will remain headquartered in Fort Wayne, Indiana.…
The post Nitinol supplier Fort Wayne Metals sold appeared first on Medical Design and Outsourcing.
MyFILM: A Pilot Study for Social-Emotional Learning in Clinical Youth
Interventions: Behavioral: MyFILM
Sponsors: Mark Sinyor
Not yet recruiting
The COMET Study: a Prospective COhort of MEdical residenTs to Assess Professional, Personal and Psychological Trajectories of Residents in General Internal Medicine
Sponsors: University of Fribourg; Insel Gruppe AG, University Hospital Bern; Hôpital Fribourgeois; University of Lausanne Hospitals
Recruiting
Evaluation of a Remote Behavioural Stress Recovery Intervention for Myocardial Infarction Patients Younger Than Fifty-five (BRIM-55): A Feasibility Study
Interventions: Behavioral: Remote-delivery Balance in Everyday Life (rBEL) Program for Myocardial Infarction Patients Younger Than 55 Years With Cardiac Distress
Sponsors: Uppsala University
Not yet recruiting
Artificial Intelligence-based Parkinson’s Disease Risk Assessment (AI-PRA) Study
Interventions: Device: Smartwatch and phone app
Sponsors: Queen Mary University of London; Hospital Ruber Internacional; University Hospital, Toulouse; Aristotle University Of Thessaloniki
Not yet recruiting

